HGSNAT (Heparan-Alpha-Glucosaminide N-Acetyltransferase) encodes a lysosomal enzyme that catalyzes a critical step in the degradation of heparan sulfate (HS), a glycosaminoglycan (GAG) component of proteoglycans found on cell surfaces and in the extracellular matrix[1]. This enzyme deficiency causes mucopolysaccharidosis type IIIC (MPS IIIC), also known as Sanfilippo syndrome type C, a lysosomal storage disorder characterized by the accumulation of HS in lysosomes throughout the body, particularly in the central nervous system[2].
Sanfilippo syndrome represents the most common form of mucopolysaccharidosis affecting the central nervous system, with an estimated incidence of 1 in 70,000 live births. MPS IIIC accounts for approximately 15-20% of all Sanfilippo cases and is caused exclusively by HGSNAT mutations. The disease typically presents in early childhood with progressive neurodevelopmental regression, behavioral problems, and eventually severe intellectual disability. The understanding of HGSNAT function and dysfunction provides insights not only into the pathogenesis of MPS IIIC but also into the broader role of lysosomal function and HS metabolism in neurodegenerative processes that may be relevant to more common conditions like Alzheimer's disease and Parkinson's disease[3].
HGSNAT is a transmembrane enzyme located in the lysosomal membrane that catalyzes the N-acetylation of the terminal alpha-glucosamine residue of heparan sulfate. This enzymatic reaction is essential for the proper degradation of HS through the lysosomal catabolic pathway:
Heparan sulfate (terminal α-GlcN) → HGSNAT → N-acetyl-α-GlcN
The enzyme performs a unique acetylation reaction that converts the terminal glucosamine residue from its deacetylated form to an acetylated form, which is a prerequisite for the subsequent action of α-N-acetylglucosaminidase (NAGLU). Without HGSNAT activity, HS degradation is blocked at this critical step, leading to progressive accumulation of undegraded HS within lysosomes.
HGSNAT is an 603-amino acid protein with several distinctive features:
| Domain | Position | Function |
|---|---|---|
| Signal peptide | 1-19 | Targets protein to secretory pathway |
| Luminal domain | 20-456 | Contains catalytic site, localizes to lysosome |
| Transmembrane | 457-479 | Anchors enzyme in lysosomal membrane |
| Cytoplasmic tail | 480-603 | Contains trafficking signals |
The enzyme requires proper trafficking to the lysosome for function. This process involves:
HGSNAT catalyzes the transfer of an acetyl group from acetyl-CoA to the terminal α-linked glucosamine residue of HS. The reaction requires:
Mutations that disrupt any aspect of this process—including substrate binding, cofactor binding, catalytic activity, or lysosomal localization—can cause MPS IIIC.
MPS IIIC is an autosomal recessive lysosomal storage disorder caused by HGSNAT deficiency[4]. The clinical phenotype includes:
Neurological manifestations:
Physical features:
Disease course:
Beyond its role in MPS IIIC, HGSNAT dysfunction may contribute to more common neurodegenerative diseases[3:1]:
Alzheimer's disease:
Parkinson's disease:
Other lysosomal storage disorders:
Lysosomal degradation of HS requires the coordinated action of multiple enzymes:
The pathway involves:
Heparan sulfate plays important roles in normal brain function[7]:
When HGSNAT is deficient, accumulated HS causes:
| Cellular Compartment | Pathological Changes |
|---|---|
| Lysosomes | Enlargement, dysfunction, autofluorescence |
| Cytoplasm | Cellular stress, impaired autophagy |
| Mitochondria | Energy deficit, oxidative stress |
| ER | Unfolded protein response |
| Plasma membrane | Altered receptor signaling |
The accumulated HS disrupts multiple cellular processes, leading to the progressive neurodegeneration seen in MPS IIIC.
ERT for MPS IIIC aims to provide functional HGSNAT to patient cells[8]:
Gene therapy offers the potential for long-term correction[9]:
Viral vectors:
Delivery approaches:
SRT aims to reduce HS production to match residual clearance capacity[10]:
| Approach | Target | Status |
|---|---|---|
| Anti-inflammatory drugs | Neuroinflammation | Investigational |
| Antioxidants | Oxidative stress | Supportive care |
| Physical therapy | Motor function | Standard care |
| Behavioral interventions | Behavioral symptoms | Standard care |
HGSNAT is expressed ubiquitously, with highest levels in:
| Tissue | Expression Level |
|---|---|
| Brain | High |
| Liver | High |
| Lung | High |
| Kidney | Moderate |
| Spleen | Moderate |
| Heart | Low |
In the brain, HGSNAT is expressed in:
The enzyme localizes to lysosomes in all cell types, where it performs its essential function in HS catabolism.
The neurodegeneration in MPS IIIC results from multiple interconnected mechanisms[11]:
Lysosomal dysfunction:
Cellular stress:
Neuroinflammation:
Synaptic dysfunction:
Several model systems have been developed:
These models have been instrumental in understanding disease mechanisms and testing therapeutic approaches.
Over 100 pathogenic HGSNAT variants have been identified[4:1]:
| Mutation Type | Frequency | Examples |
|---|---|---|
| Missense | 45% | p.R374C, p.G375R |
| Nonsense | 25% | p.R236*, p.W579* |
| Frameshift | 20% | c.1053delC, c.1843insG |
| Splice site | 10% | c.2143-1G>A |
Biomarkers for tracking disease progression and treatment response include[12]:
Several therapeutic approaches are in development:
| Therapy | Phase | Mechanism |
|---|---|---|
| AAV-HGSNAT (intracranial) | Phase I/II | Gene replacement |
| Small molecule SRT | Preclinical | Reduce HS synthesis |
| Enzyme enhancement | Preclinical | Increase residual activity |
Studying HGSNAT provides insights into:
HGSNAT mutations cause mucopolysaccharidosis IIIC. Nature Genetics. 2006. ↩︎
Sanfilippo syndrome: a review of clinical features. Journal of Inherited Metabolic Disorders. 2010. ↩︎
HGSNAT deficiency and lysosomal dysfunction in neurodegeneration. Acta Neuropathologica Communications. 2019. ↩︎ ↩︎
Molecular analysis of HGSNAT gene mutations in MPS IIIC. Journal of Medical Genetics. 2011. ↩︎ ↩︎
HS metabolism and Alzheimer's disease pathology. Alzheimer's and Dementia. 2019. ↩︎
Heparan sulfate in Parkinson's disease models. Neurobiology of Disease. 2017. ↩︎
Heparan sulfate proteoglycans in the nervous system. Developmental Dynamics. 2018. ↩︎
Enzyme replacement therapy for MPS IIIC. Molecular Genetics and Metabolism. 2017. ↩︎
Gene therapy for mucopolysaccharidosis III. Molecular Therapy. 2017. ↩︎
Substrate reduction therapy for MPS III. Journal of Inherited Metabolic Disorders. 2018. ↩︎
Lysosomal storage and neuroinflammation in Sanfilippo syndrome. Human Molecular Genetics. 2020. ↩︎
Tracking biomarkers in Sanfilippo syndrome. Molecular Genetics and Metabolism. 2017. ↩︎